Moslehi Nazanin, Vafa Mohammadreza, Rahimi-Foroushani Abbas, Golestan Banafsheh
Departments of Nutrition, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
J Res Med Sci. 2012 Jul;17(7):607-14.
This study aimed to investigate whether magnesium supplementation might affect serum magnesium, high sensitive C-reactive protein (hs-CRP), plasma fibrinogen, and interleukin 6 (IL-6) levels in healthy middle-aged overweight women. The relationships, if any, between serum magnesium and the inflammatory markers were also examined cross-sectionally in the entire participants at the beginning of the study.
This double-blinded, placebo-controlled, randomized trial included 74 middle-aged overweight women. Participants were randomly assigned to receive either 250 mg magnesium as magnesium oxide or placebo daily for 8 weeks. Serum magnesium, hs-CRP, fibrinogen and IL-6 concentrations were measured before and after the intervention.
Serum magnesium was found to be inversely correlated with hs-CRP (rs =-0.22, P=0.05) in the entire participants at baseline. Serum hs-CRP declined significantly in both groups as compared with baseline values (median change=0.8 mg/L; PMagnesium= 0.03, PPlacebo < 0.001). Plasma fibrinogen decreased significantly, by 9%, in the magnesium group at the end of week 8 compared to baseline (P=0.001). Mean concentration of IL-6 was significantly increased in the magnesium group comparing the baseline value(P=0.001). However hs-CRP, fibrinogen and IL-6 levels at week 8 or any changes during the study were not statistically different between the two groups. Serum magnesium showed no significant changes in any groups.
Serum magnesium had a significant inverse correlation with hs-CRP. In the present study, magnesium as magnesium oxide, 250 mg/day, for 8 weeks did not significantly attenuate inflammatory markers in the magnesium group as compared to the placebo.
本研究旨在调查补充镁是否会影响健康中年超重女性的血清镁、高敏C反应蛋白（hs-CRP）、血浆纤维蛋白原和白细胞介素6（IL-6）水平。在研究开始时，还对所有参与者的血清镁与炎症标志物之间的关系进行了横断面研究。
这项双盲、安慰剂对照、随机试验纳入了74名中年超重女性。参与者被随机分配，每天接受250毫克氧化镁形式的镁或安慰剂，为期8周。在干预前后测量血清镁、hs-CRP、纤维蛋白原和IL-6浓度。
在基线时，所有参与者的血清镁与hs-CRP呈负相关（rs = -0.22，P = 0.05）。与基线值相比，两组的血清hs-CRP均显著下降（中位数变化 = 0.8毫克/升；镁组P = 0.03，安慰剂组P < 0.001）。与基线相比，镁组在第8周结束时血浆纤维蛋白原显著下降了9%（P = 0.001）。与基线值相比，镁组的IL-6平均浓度显著升高（P = 0.001）。然而，两组在第8周时的hs-CRP、纤维蛋白原和IL-6水平或研究期间的任何变化在统计学上均无差异。任何组的血清镁均无显著变化。
血清镁与hs-CRP呈显著负相关。在本研究中，与安慰剂相比，每天250毫克氧化镁形式的镁服用8周，并未使镁组的炎症标志物显著减弱。
